SGLT2 inhibitors and GLP-1 receptor agonists lower cardiovascular risk in type 2 diabetes, but a recent review suggests that ...

Investigators examined the comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in a real-world setting.

Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

SGLT2 inhibitors were developed to lower blood sugar in type 2 diabetes. But they do have other uses. Some of them are approved for chronic kidney disease. They also can treat heart failure.

SGLT2 inhibitor use may help stabilize eGFR levels for patients with autosomal dominant polycystic kidney disease and type 2 diabetes, according to study data.“Given its unique pathophysiology, ...

SGLT2 inhibitors are medications designed to help manage blood sugar in people living with type 2 diabetes. Learn more about the different types, as well as the benefits and side effects.

If SGLT2 inhibitors or GLP1R agonists had been developed before RAAS inhibitors, we would most likely face the same challenge in showing an additional benefit of RAAS inhibition.

Despite incomplete evidence, longevity enthusiasts are experimenting with SGLT2 inhibitors in their quest to live healthier ...

After the SGLT2 inhibitors were shown to benefit patients with type 2 diabetes, reducing cardiovascular events, including hospitalization for heart failure, the next natural research question ...

The SGLT2 inhibitor group was matched by age and sex with a group of 325,989 adults with diabetes who did not use an SGLT2 inhibitor. The occurrence of cancer was the primary outcome.

SGLT2 inhibitors have diuretic and anti-inflammatory effects that may contribute to improved outcomes in patients with PAH, particularly for those who have left-sided heart disease or other ...

SGLT2 inhibitors did not reduce the risk for adverse liver outcomes more than DPP-4 inhibitors in patients with type 2 diabetes and metabolic dysfunction–associated steatotic liver disease.